RestorGenex Announces Management Changes
7/9/2014 11:01:49 AM
RestorGenex Corporation (OTCQB: RESX), a specialty biopharmaceutical company initially focused on developing products for dermatology, ophthalmology and women’s health, announced today several management changes.
RestorGenex has appointed Phillip B. Donenberg as its chief financial offer. Mr. Donenberg has served biotech and pharmaceutical companies in financial positions for over 20 years. Before RestorGenex, he served as BioSante Pharmaceuticals, Inc.’s Senior Vice President of Finance from 2010 until June 19, 2013 and Chief Financial Officer and Secretary from 1998 until June 19, 2013 when BioSante merged with ANIP Acquisition Company, d/b/a ANI Pharmaceuticals, Inc.
Help employers find you! Check out all the jobs and post your resume.
comments powered by